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Abstract
Background: Embolic events (EE) in infective endocarditis (IE) are caused by fragmentation of vegetations or valvular tissue.
Vegetation length is considered to be the most potent predictor of EE, but does not take into account the degree of
friability of the vegetation and of the surrounded infected tissue. Matrix metalloproteinases (MMPs) are enzymes involved in
degradation of matrix extracellular components and play a role in the pathophysiology of IE. We aimed to determine
whether, in addition to the vegetation size, circulating MMPs could provide accurate predictive value of embolism in IE.
Methods: Among 145 patients referred for a native valve IE, we prospectively included 16 patients who experienced EE
during antibiotic therapy (new-EE) and 30 patients without new-EE and treated without valvular surgery. A control group of
38 patients with a degenerative valvular heart disease was also included. In addition to clinical, microbiological and
echocardiographic assessment, blood MMPs and their inhibitors were assayed in all patients at admission.
Results: MMP-9 serum level was significantly higher in patients with new-EE compared to controls (median [interquartile
range]; 250 ng/mL [175–455] vs. 111 ng/mL [70–144], respectively; p,0.0001) and patients with no new-EE (250 ng/mL
[175–455] vs. 138 ng/mL [95–232]; p,0.01). A higher MMP-9 activity in patients who experienced new-EE was further
confirmed by gelatin zymography analysis. Circulating MMP-9 remains a predictor of new-EE after adjustment for vegetation
length and other potential confounders. This parameter provided incremental predictive value over vegetation
measurements.
Conclusions: MMP-9 serum level is associated with the risk of embolism during IE. This marker might help physicians in the
management of the disease, but further propspective studies are need to confirm these preliminary results.
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Introduction
The endocardial involvement in infective endocarditis (IE)
results in tissue damages and direct contact between blood and the
subendothelial host components including proteins of the extra-
cellular matrix, thromboplastin, and tissue factor, which trigger
blood coagulation and development of vegetations [1,2]. Valvular
endocardium can be severely damaged by pathogens toxins and
mediators of the host inflammatory response. Then, tissue
remodeling and neo-angiogenesis components (proteolysis and
chemotaxis) destroy progressively the valve, increasing the risk of
valvular insufficiency, abscesses and cardiac embolization [3].
Emboli are believed to be caused by fragmentation of both
vegetations and surrounded valvular tissue. These embolic events
(EE) are a frequent and life-threatening complication of IE
occurring in 20% to 80% of patients [4,5,6,7,8]. Currently, the
risk of embolism after diagnosis remains about 6% to 21% despite
a recommended management including a rapid institution of
antimicrobial treatment in all patients and valvular surgery in
those with higher risk [5,6]. Although vegetation length is
considered as the most potent predictor of EE, it still remains
controversial because it does not take into account the degree of
friability of the vegetation and the fragility of the surrounded
infected tissues [9]. Thus, the risk of emboli might be determined
by the intensity of the coagulation/fibrinolysis activity or by the
local inflammatory response and tissue remodeling.
Matrix metalloproteinases (MMPs) constitute a family of
endopeptidases having in common the presence of zinc atom in
their active site, a Ca
2+ dependency for their activity, and the
ability to interact with specific tissue inhibitors of metalloprotei-
nases (TIMPs) to form enzymatically inactive complexes. MMPs
are synthesized as enzymatically inactive precursors by a variety of
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18830parenchymal, connective tissue, and inflammatory cells. They
show a wide range of specificity for different substrates, including
native and partially degraded fibrillar collagens, basement
membrane collagens, proteoglycans, elastin, and fibronectin.
MMPs, alone or in concert with the plasminogen/plasmin system,
are involved in the degradation of extra-cellular matrix compo-
nents, a requirement for cell migration and tissue remodeling,
which play an essential role in many pathological processes such as
degenerative valvular heart diseases and endocarditis [10,11].
Recently, we showed, in a transcriptional profile analysis, a
significant up-regulation of many MMPs genes in the cardiac
valves during native IE in comparison with degenerative heart
valve diseases [3].
Therefore, we aimed to analyze the role of MMPs and TIMPs
on the subsequent risk of embolism during IE in addition to the
vegetation size.
Methods
Ethics Statement
Written informed consent was obtained from all participating
patients, as required by the institutional review board under an
approved protocol (Comite ´ de Protection des Personnes Sud
Me ´diterrane ´e V, number A00114-51).
Patients and Controls
From January 2005 to April 2008, all consecutive patients
admitted in the Department of Cardiology with the diagnosis of
definite native valve IE, according to the modified Duke criteria
[12], were eligible for the study entry. Blood cultures and initial
clinical, and echocardiographic were systematically performed in
all patients at baseline (before the initiation of adequate antibiotic
therapy). All patients were followed during their hospital stay and
were divided into two groups according to the occurrence of EE
during the hospitalization after the beginning of the adequate
antibiotic therapy (new-EE). Diagnosis of new-EE was based on
clinical and computed tomography scans data. Specific diagnosis
of cerebral embolism was confirmed by an experienced neurologist
during the clinical course. Since repeated imaging investigations
were not systematically performed, silent EE were not included.
Cutaneous manifestations or emboli occurring after surgery were
not included. The exclusion criteria were: age ,18 years,
pregnancy, patients under anticoagulation or antiplatelets treat-
ment, patients with abnormalities of hemostasis, and patients who
underwent blood samples collection for MMPs and TIMPs assays
.48 hours after the beginning of adequate antibiotic therapy.
Since valvular surgery suppresses the risk of IE-related embolism,
the patients of the no new-EE group who were operated on during
the course of antibiotic therapy were excluded from the analysis.
The control group consisted of patients with degenerative
valvular heart diseases referred to our Department before cardiac
surgery during the same period. We planned to include a similar
number of controls than that of IE patients.
Clinical, Biological and Echocardiographic Data
The following clinical and biological parameters were prospec-
tively collected at baseline: age, sex, diabetes, history of cancer,
comorbidity [13], heart failure (HF), previous EE, serum
Figure 1. Flow chart showing enrollment of study patients.
doi:10.1371/journal.pone.0018830.g001
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white cells and platelets counts. Trans-thoracic and trans-
esophageal echocardiography (TTE and TEE) were performed
at baseline in all cases, as previously reported [4]. Echocardio-
graphic data included the presence and maximal length of
vegetation [6]. Measurements of vegetation length were performed
in various planes by TTE and TEE, and maximal length was used
for analysis. In the presence of multiple vegetations, the largest
length was used for analysis. A cut-off value of 10 mm was used
because it was demonstrated to be predictive of new-EE in a large
population of patients with left and right-sided IE. [6] An abscess
was defined as a thickened area or mass with a heterogeneous
echogenic or echolucent appearance [14]. Echocardiographic data
were stored electronically and used unaltered for subsequent
analysis.
MMPs and TIMPs Assays
Blood samples were collected before or within the 48 hours after
the beginning of the adequate antibiotic therapy. MMP-1, MMP-
2, MMP-3 and MMP-8 were measured simultaneously as well as
TIMP-1, TIMP-2, TIMP-3, TIMP-4 while MMP-9 was measured
in a separate test. MMPs and TIMPs were assayed in individual
human serum samples using FluorokineH MultiAnalyte Profiling
(F-MAP) kits from R&D Systems (Minneapolis, MN, USA). Kits
were run on a LuminexH 100 IS Bioanalyzer (Qiagen, France)
according to the kit manufacturer’s instructions. Briefly, Fluor-
okineH MultiAnalyte Profiling kits contained distinct groups of
microspheres (each group bearing unique fluorescence intensity
and a specific antibody), biotinylated antibodies, and phycoery-
thrin-conjugated streptavidin. Serum samples were incubated with
antibody-coated microspheres binding to specific targets in the
serum. Microsphere complexes were washed and incubated with
biotinylated antibodies. A final incubation was performed in which
phycoerythrin-labeled streptavidin was allowed to bind to
biotinylated antibodies present on microspheres. Microspheres
were then loaded into a LuminexH 100 Bioanalyzer, which
quantifies the amount of phycoerythrin fluorescence present on
each of the distinct microsphere groups. At least 50 individual
microspheres were counted for each sample, and the median
fluorescence intensity was used for subsequent calculations. Each
of the microsphere sets was reported by the manufacturer to
exhibit less than 0.5% cross-reactivity and interference with the
other MMP or TIMP family members studied.
Zymography
1:20 diluted serum samples (10 ml) were added to non-reducing
sample buffer (1/3, v/v) and loaded on to 10% SDS–polyacrya-
mide gels containing copolymerized gelatin (0.1%, w/v) (Sigma
Table 1. Baseline Characteristics of The Patient Population.
Controls No new-EE New-EE p* p{
(n=38) (n=30) (n=16)
Age, years 70 (62–79) 71 (61–75) 57 (33–70) 0.005 0.02
Male 16 (42) 24 (80) 10 (63) 0.17 0.20
Cancer 5 (13) 4 (13) 2 (13) 1.0 1.0
Diabetes 3 (8) 8 (27) 1 (6) 1.0 0.13
Comorbidity index .2 20 (53) 20 (67) 6 (38) 0.30 0.06
Heart failure 11 (29) 9 (30) 4 (25) 1.0 1.0
Serum creatinine, mmol/L 92 (72–110) 96(80–138) 87 (73–96) 0.32 0.14
Hemoglobin, g/L 130 (130–140) 113 (99–125) 115 (96–122) 0.002 0.76
White cell count, x10
9/L 7.4 (6.2–9.0) 8.9 (6.9–11.7) 11.7 (6.1–14.9) 0.04 0.20
Neutrophils, x10
9/L 4.8 (4.0–6.1) 6.7 (4.9–10.2) 9.5 (4.1–11.7) 0.02 0.24
Platelets, x10
9/L 238 (205–298) 282 (200–372) 324 (237–381) 0.12 0.53
C-reactive protein, mg/L 4 (2–7) 93 (20–172) 89 (66–169) ,0.0001 0.63
Vegetation length, mm NA 10 (5–12) 15 (10–20) NA 0.02
Infected valves
Aortic NA 8 (27) 8 (50) NA 0.11
Mitral NA 16 (53) 5 (31) NA 0.15
Right only NA 7 (23) 4 (25) NA 1.0
Multivalvular NA 2 (7) 2 (13) NA 0.6
Embolic event before diagnosis of IE NA 12 (40) 3 (19) NA 0.19
Abscess NA 3 (10) 2 (13) NA 1.0
Causative pathogens
Streptococci NA 10 (33) 7 (44) NA 0.48
Staphylococci NA 9 (30) 4 (25) NA 1.0
Enterococci NA 3 (10) 2 (13) NA 1.0
Others NA 4 (13) 1 (6) NA 0.64
No pathogens identified NA 4 (13) 2 (13) NA 1.0
doi:10.1371/journal.pone.0018830.t001
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performed at 75V for 0.5 h then at 100 V for 2 h at 4uC. The
gels were then rinsed twice with 2.5% Triton X-100 to remove
SDS and renature the MMPs. After a brief wash in distilled water
gels were incubated overnight at 37uC in 50 mM Tris–HCl buffer
pH 7.6 containing 5 mM CaCl2, 200 mM NaCl and Brij 35
(0.02%) with gentle agitation. The gels were stained with
Coomassie
TM Blue (Sigma) and MMP activities were detected as
transparent bands on the blue background. The Scion Image
software was used for quantification of the bands after image
acquisition (LFG application software) with a CCD camera.
Statistical Analysis
Categorical variables, expressed as absolute values and
percentage, were compared by x
2 test or Fisher exact test (two
tailed) if the expected count in any cell was ,5. Continuous
variables, expressed as median (interquartile range), were
compared by Mann-Whitney test (comparison between two
groups) or Kruskal-Wallis test (comparison of more than two
groups) with Dunn’s multiple comparisons post-hoc test when
significant. The association between continuous variables was
carried out by using the Spearman rho coefficient.
Odds ratio (OR) and their 95% confidence interval (CI),
calculated by logistic regression, were used as measurements of the
clinical impact of the predictor variables. For continuous variables,
OR were expressed for 1-standard deviation (SD) increase.
Since MMP-9 serum level was significantly associated with new-
EE, a receiver operating characteristic (ROC) curve analysis was
performed to compare the predictive values of circulating MMP-9
and vegetation length. ROC curve was also used to determine the
optimal cut-off value of MMP-9 that best predicted the event. An
adjustment for vegetation length (known to be predicted of new-
EE)[6] and for the other biological parameters significantly
correlated with circulating MMP-9 was performed by logistic
regression analysis.
P#0.05 was considered significant. All analyses were performed
with SPSS for Windows 16.0 (SPSS Inc.,Chicago, IL, USA).
Results
Patient Characteristics
During the study period, 145 patients with a definite diagnosis
of native valve IE were hospitalized in our department. Forty-six
patients were finally enrolled according to the eligibility criteria; 30
patients in the no new-EE group and 16 patients in the new-EE
group (Figure 1). New-EE occurred after a median time of 5.5 days
(range, 1 to 26) after institution of adequate antibiotic therapy.
Sites of embolization were central nervous system (6 cases),
Figure 2. Results of the MMPs and TIMPs serum levels. Only MMP-9 serum level was significantly higher in patients with new-EE compared to
controls and patients with no new-EE. Medians and interquartile ranges are shown.
doi:10.1371/journal.pone.0018830.g002
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spleen (2 cases), retina (1 case), and coronary circulation (1 case).
During the same period, 38 patients with a degenerative valvular
heart disease were included in the control group. The character-
istics of the three groups are summarized in the Table 1.
Patients with new-EE exhibited larger vegetations compared to
patients without new-EE (15 mm [10–20] vs. 10 mm [5–12],
respectively; p=0.02).
MMPs and TIMPs
Comparison of MMPs and TIMPs level in serum according to
the three study groups are shown in the Figure 2. Only MMP-9
serum level was significantly higher in patients with new-EE
compared to controls (250 ng/mL [175–455] vs. 111 ng/mL [70–
144], respectively; p,0.0001) and patients with no new-EE
(250 ng/mL [175-455] vs. 138 ng/mL [95–232]; p,0.01). The
difference remained significant after exclusion of patients who had
experienced an embolic event before the antibiotic treatment and
blood collection (p=0.01).
No significant correlation was observed between MMP-9 serum
level and CRP (rho=0.16; p=0.28), hemoglobin concentration
(rho=0.02; p=0.88), creatinine serum level (rho=20.23;
p=0.12), and platelets count (rho=0.16; p=0.29). However,
MMP-9 serum level was significantly correlated with neutrophils
count (rho=0.49; p=0.001), MMP-8 serum level (rho=0.71;
p,0.0001), and vegetation length (rho=0.38; p=0.01).
A higher MMP-9 activity in patients who experienced new-EE
was further confirmed by gelatin zymography analysis (Figure 3).
Prediction of New-EE
Using single-variable analysis, vegetation length (OR per 1-SD
increase =2.2; 95% CI, 1.04 to 4.56; p=0.04) and MMP-9 serum
level (OR per 1-SD increase=3.2; 95% CI, 1.40 to 7.44;
p=0.006) appeared to be predictors of new-EE. Analysis of the
ROC curves revealed that the area under the curve was slightly
higher for MMP-9 serum level compared to vegetation length
(Figure 4). Furthermore, MMP-9 serum level remained predictor
of new-EE after adjustment for vegetation length, neutrophils
count, and MMP-8 serum level (Table 2). A MMP-9 level
threshold of 167 ng/mL was identified as having the highest
predictive value for new-EE by the ROC curve analysis. Indeed,
new-EE occurred more frequently in patients with MMP-9 serum
Figure 3. Gelatinolytic activity of MMP-9 (92 kDa) evaluated by in-gel zymography. A: Gelatinolytic activity is greater in New-EE patients.
B: Densitometric analysis of the values of gelatinase activity expressed as arbitrary units (AR). Results are given as means 6SEM. *p,0.0001 vs.
Controls; {p=0.05 versus No new-EE patients.
doi:10.1371/journal.pone.0018830.g003
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#167 ng/mL (50% [13/26] vs. 15% [3/20]; p=0.03).
MMP-9 assays provided incremental predictive value over
vegetation measurements (Table 3). Among the patients with both
vegetation .10 mm and MMP-9 serum level .167 ng/mL at
admission, the incidence of new-EE under medical treatment was
64% (OR=6.4; 95% CI, 1.6 to 25.5; p=0.008) (Figure 5).
Discussion
The present study is the first demonstrating the possible role of
MMP-9 in the pathogenesis of EE during IE. We showed that
circulating MMP-9 has an independent predictive value of emboli
and provides incremental prognostic information over the
echocardiographic data collected at admission.
Embolic Risk in Infective Endocarditis
During IE the majority of EE involves the central nervous
system exposing patients to a higher risk of death [15]. Antibiotics
are known to decrease the risk of embolism [5,6,16], but in some
patients, EE can occur despite this adequate medical therapy.
Those high-risk patients have been identified to have more
frequently vegetations larger than 10 mm [6]. Therefore, the
recent international guidelines have recommended to perform
early valvular surgery according to the vegetation length and the
presence of previous EE [17,18,19]. However, despite this
therapeutic strategy based on the vegetation length, the incidence
of EE remains between 6% to 21% in the most recent series
[5,6,16,20]. This could be explained by a surgical treatment
performed too late in patients with large vegetations, and also by
the limitations of the vegetation length predictive value. Thus, we
decided to initiate the present study in order to identify biomarkers
that could help in the tricky decision of surgical indication in
prevention of EE. Few previous works attempted to find such a
biological parameters. Kupferwasser et al. found that, identifica-
tion of infection-associated antiphospholipid antibodies in patients
with IE was associated with a higher rate of EE. However, one of
the limitations in their study was the inclusion in the analysis of EE
(9/26) that had occurred before the admission and blood
collection [21]. Two other investigations focussed their analysis
on the impact of endothelial cell and platelet activation, systemic
coagulation activity, and fibrinolytic capacity on the subsequent
risk of thromboembolic events. These events were associated with
an increased serum level of many markers of thrombus formation
but no cut-off value was identified for each of those and their
Figure 4. Receiver Operating Characteristic curves analysis using vegetation length and MMP-9 serum level as predictors of new-
EE. The area under de curves are given with their 95% confidence interval.
doi:10.1371/journal.pone.0018830.g004
Table 2. Predictors of New-EE by Multivariable Analysis.
Adjusted OR per
1-SD increase 95% CI p
MMP-9, ng/mL 3.5 1.19 to 10.34 0.02
MMP-8, ng/mL 0.8 0.32 to 2.13 0.70
Neutrophils, x10
9/L 0.9 0.40 to 2.08 0.81
Vegetation length, mm 1.9 0.89 to 4.20 0.10
OR=odds ratio; SD=standard deviation; CI=confidence interval.
doi:10.1371/journal.pone.0018830.t002
Table 3. Predictive Values of The Different Risk Stratification
Strategies.
PPV (%) NPV (%) OR (95% CI) p
Vegetation length .10 mm 43 78 4.4 (1.2 to 16.2) 0.03
MMP-9.167 ng/mL 50 85 5.7 (1.3 to 24.1) 0.02
Vegetation length .10 mm 64 78 6.4 (1.6 to 25.5) 0.008
and
MMP-9.167 ng/mL
PPV=positive predictive value; NPV=negative predictive value; OR=odds
ratio; CI=confidence interval.
doi:10.1371/journal.pone.0018830.t003
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vegetation length, which remains the most validated predictor of
EE [22,23].
MMPs in Infective Endocarditis
Based on the pathophysiological concepts of IE, we aimed to
analyze the impact of MMPs on the subsequent risk of embolism
because these molecules seem to be involved in many steps of the
IE pathogenesis [3,24,25,26]. Moreover, we decided to analyze
the relationship between these molecules and the vegetations
length.
Matrix metalloproteinases are involved in many normal and
pathological processes such as myxomatous valvular heart disease
[27], atherosclerosis plaque instability [28], aneurysm develop-
ment [29], cancer [30], heart failure[31] and infectious diseases
[10]. In normal conditions, MMPs are produced by inflammatory
(neutrophils and macrophages) and other resident cells. Cytokines
and growth factors including IL-1, IL-10, platelet-derived growth
factor, and TNF-a have been shown to induce or stimulate MMPs
synthesis [31,32,33]. The MMPs play a role in infectious diseases
when the host immune system is challenged by an invading
organism, facilitating the recruitment of leucocytes from the
bloodstream for eradication of the pathogen and modulating the
inflammatory response [10]. In addition, they participate to the
coagulation/fibrinolytic system and thus may play a role in the
coagulation/fibrinolytic response to infection [34]. However, the
excess of MMP activity following infection may cause immuno-
pathological processes that lead to host morbidity or mortality and
favor pathogen dissemination or persistence [10]. Indeed, some
studies found an over expression of MMPs in valvular tissues of IE
and strongly suggested that MMPs participated to the tissue
destruction, layers disruption and neovascularization observed
during IE [3,24,25]. Moreover, the role of MMPs in embolic
events has been demonstrated in many pathological processes such
as atherosclerotic plaque rupture[28] and cardiac myxoma [35].
Recently, we showed, in a transcriptional profile analysis, a
significant up-regulation of many MMPs genes in the cardiac
valves during native IE in comparison with degenerative heart
valve diseases [3]. In this latter study, MMP-12 was especially
associated with IE, but also MMP-9. In the present work, MMP-
12 was not assessed because its serum level is diffcult to obtain in
comparison to the others. By demonstrating that circulating
MMP-9, also known as 92-kDa gelatinase, was strongly associated
with IE-related emboli, our study suggests that an intense local
valvular inflammation can lead to MMP-9 overexpression, and
then to promote EE by increasing the fragility of the cardiac
infected tissue and vegetations. Hence, there may be an increased
release of this enzyme into the circulation from the infected tissues
themselves or by circulating macrophages or neutrophils involved
in the inflammatory response. On the other hand, this increase
might represent a marker of end organ ischemia after EE.
However, in our study the MMP-9 serum level remained
predictive of new-EE after exclusion of patients who had
experienced EE before the blood sample collection.
Although we did not find a significant correlation between
circulating MMP-9 and CRP, the high level of circulating MMP-9
associated with EE may reflect a more important local
inflammatory reaction leading to a high fragility of vegetations
and surrounded tisues.
In the present study, we showed a higher prognostic value of
MMP-9 and MMP-8 compred to the other metalloproteinases.
One explanation would be that, in the context of infectious
disease, neutrophils MMP-9 and -8 can be released immediately
after stimulation, whereas the others required a longer process of
increase gene transcription to drive secretion. Moreover, it has
been shown that some pathogens can induce secretion of MMP-9
by host cells, but also activated (cleaved) it by secreting proteolytic
enzymes [10]. Finally, the absence of significant changes in TIMP
serum level in IE emphasized the shift in the balance of circulating
enzymes towards proteolysis and then tissue destruction and
embolization.
Vegetation Length and MMPs in Prediction of Embolism
In accordance with other previous studies [5,6], we found
vegetation length as a predictor of new-EE. Among patients with
vegetation length .10 mm at admission, 43% experienced emboli
during antibiotic therapy. Besides, MMP-9 serum level was also
predictive of new-EE independently from vegetation length and
with a higher predictive value. Our results indicate that 50% of the
patients with circulating MMP-9 .167 ng/mL at admission
experienced new-EE during antibiotic therapy. In addition, we
tested, for the first time, the use of an echocardiographic and a
biological parameter in the prediction of EE under medical
treatment. Thus, the better predictive value was obtained with the
combination of the two parameters since 64% of patients with
both vegetation length .10 mm and MMP-9 .167 ng/mL
experienced EE under medical treatment whereas only 8% had
EE in absence of the two criteria. These results suggest that not
only the size of vegetation influences the embolic risk but also its
instability as well as the friability of the surrounded infected
cardiac tissues as determined by MMP-9 activity.
Limitations
The rates of emboli under IE treatment in the present study
were much higher than those previously published because of a
specific design. Indeed, in the European multicenter study, the rate
of EE under antibiotic therapy was 7.3%, but in this analysis the
patients who underwent surgery before the occurrence of EE were
included.s[6] Since those patients were excluded in the present
work, the rate of new-EE observed is rather representative of the
risk of embolism under medical therapy alone than the risk
observed if the current recommendations of surgical management
are applied. However, using the current study design, we believe
Figure 5. Incidence of new-EE according to the results of
vegetation length and MMP-9 serum level. There was an
incremental predictive value of MMP-9 over the vegetation length.
doi:10.1371/journal.pone.0018830.g005
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a potential EE was limited.
No analysis of MMPs during follow-up was performed, thus, we
were unable to establish the time course of MMP-9 activity in the
patients with new-EE and the others. In this study, silent EE were
not systematically investigated, thus their occurrence could
influence our results.
Clinical Implications and Conclusions
Although recent international guidelines recommend to perform
early valvular surgery in patients with large vegetations associated
with recurrent emboli or other indications of surgery, the decision
to operate can be more difficult in patients with isolated large
vegetations. Our study identified circulating MMP-9 as a possible
biomarker of the embolic risk. This parameter might be used in
association with the vegetation length to predict EE under medical
therapy and then to indicate surgery. However, further investiga-
tions are required to confirm these preliminary results and to assess
their utility in the clinical practice.
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